Xuan-Xuan Yu, Zi-Yao Zhuang, Rui-Yang Ge, Shuang Lin, Jiang-Yan Ren, Yi-Wen Zhou, Jing-Lun Zhang, Zi-Xuan Li, Ge-Fei Li, Jun Ji, Fuhua Yan, Huang Li, Jie Deng
{"title":"Resolvin D<sub>1</sub> alleviates periodontitis by promoting FPR2-dependent macrophage pro-resolving polarization and efferocytosis.","authors":"Xuan-Xuan Yu, Zi-Yao Zhuang, Rui-Yang Ge, Shuang Lin, Jiang-Yan Ren, Yi-Wen Zhou, Jing-Lun Zhang, Zi-Xuan Li, Ge-Fei Li, Jun Ji, Fuhua Yan, Huang Li, Jie Deng","doi":"10.1016/j.jare.2026.08.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Periodontitis is a chronic inflammatory disease driven by dysregulated host responses and failed resolution of inflammation, leading to progressive periodontal tissue destruction. This resolution failure is critically linked to impaired macrophage efferocytosis and a deficiency in endogenous specialized pro-resolving mediators such as Resolvin D<sub>1</sub> (RvD<sub>1</sub>).</p><p><strong>Objectives: </strong>This study aimed to determine if exogenous RvD<sub>1</sub> can restore periodontal homeostasis and to define the formyl peptide receptor 2 (FPR2)-dependent mechanisms governing macrophage reprogramming and the clearance of necroptotic cells.</p><p><strong>Methods: </strong>We integrated two independent human single-cell RNA sequencing (scRNA-seq) datasets from gingival and periodontal tissues, with a murine ligature-induced periodontitis model using wild-type (Fpr2<sup>fl/fl</sup>) and myeloid-specific Fpr2 conditional knockout (Fpr2<sup>Lyz2-cKO</sup>) mice. Therapeutic efficacy was assessed via scRNA-seq, micro-CT, and histology, while downstream molecular pathways were validated through in vivo and ex vivo plus in vitro macrophage functional and signaling assays.</p><p><strong>Results: </strong>Human scRNA-seq analysis revealed a resolution-deficient immune landscape in periodontitis, characterized by impaired macrophage efferocytosis, increased necroptotic signatures, and reduced RvD<sub>1</sub> biosynthetic capacity; these abnormalities were largely reversed following periodontal therapy. In vivo, RvD<sub>1</sub> significantly reduced alveolar bone loss and decreased necroptotic burden in Fpr2<sup>fl/fl</sup> mice but not in Fpr2<sup>Lyz2-cKO</sup> mice. Single-cell profiling demonstrated that RvD<sub>1</sub> remodeled the myeloid compartment, promoting monocyte differentiation toward pro-resolving macrophages marked by elevated expression of Chil3, Fn1, and Arg1. Pseudotime trajectory mapping, corroborated by functional engulfment assays, identified an RvD<sub>1</sub>-induced efferocytosis-competent macrophage state. Mechanistically, RvD<sub>1</sub> suppressed the p38 mitogen-activated protein kinase (MAPK)-ADAM17 signaling axis, preventing CD14 cleavage and enhancing recognition and clearance of necroptotic cells. Deletion of Fpr2 in myeloid lineage cells abolished these effects.</p><p><strong>Conclusions: </strong>This study proposes an RvD<sub>1</sub>-FPR2-p38 MAPK/ADAM17-CD14 axis that integrates macrophage reprogramming with efficient efferocytotic clearance to resolve periodontal inflammation. Targeting this pathway represents a host-directed immunomodulatory strategy for the treatment of periodontitis and potentially other chronic inflammatory diseases.</p>","PeriodicalId":94063,"journal":{"name":"Journal of advanced research","volume":" ","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of advanced research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jare.2026.08.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Periodontitis is a chronic inflammatory disease driven by dysregulated host responses and failed resolution of inflammation, leading to progressive periodontal tissue destruction. This resolution failure is critically linked to impaired macrophage efferocytosis and a deficiency in endogenous specialized pro-resolving mediators such as Resolvin D1 (RvD1).
Objectives: This study aimed to determine if exogenous RvD1 can restore periodontal homeostasis and to define the formyl peptide receptor 2 (FPR2)-dependent mechanisms governing macrophage reprogramming and the clearance of necroptotic cells.
Methods: We integrated two independent human single-cell RNA sequencing (scRNA-seq) datasets from gingival and periodontal tissues, with a murine ligature-induced periodontitis model using wild-type (Fpr2fl/fl) and myeloid-specific Fpr2 conditional knockout (Fpr2Lyz2-cKO) mice. Therapeutic efficacy was assessed via scRNA-seq, micro-CT, and histology, while downstream molecular pathways were validated through in vivo and ex vivo plus in vitro macrophage functional and signaling assays.
Results: Human scRNA-seq analysis revealed a resolution-deficient immune landscape in periodontitis, characterized by impaired macrophage efferocytosis, increased necroptotic signatures, and reduced RvD1 biosynthetic capacity; these abnormalities were largely reversed following periodontal therapy. In vivo, RvD1 significantly reduced alveolar bone loss and decreased necroptotic burden in Fpr2fl/fl mice but not in Fpr2Lyz2-cKO mice. Single-cell profiling demonstrated that RvD1 remodeled the myeloid compartment, promoting monocyte differentiation toward pro-resolving macrophages marked by elevated expression of Chil3, Fn1, and Arg1. Pseudotime trajectory mapping, corroborated by functional engulfment assays, identified an RvD1-induced efferocytosis-competent macrophage state. Mechanistically, RvD1 suppressed the p38 mitogen-activated protein kinase (MAPK)-ADAM17 signaling axis, preventing CD14 cleavage and enhancing recognition and clearance of necroptotic cells. Deletion of Fpr2 in myeloid lineage cells abolished these effects.
Conclusions: This study proposes an RvD1-FPR2-p38 MAPK/ADAM17-CD14 axis that integrates macrophage reprogramming with efficient efferocytotic clearance to resolve periodontal inflammation. Targeting this pathway represents a host-directed immunomodulatory strategy for the treatment of periodontitis and potentially other chronic inflammatory diseases.